Roche terminates aleglitazar investigation over safety issues
Based on the recommendation by the independent Data and Safety Monitoring Board to halt the trial due to safety concerns and lack of efficacy, the company decided to
The US Food and Drug Administration (FDA) has granted accelerated approval to Bristol Myers Squibb’s (BMS) Zenbexus (iberdomide), along with daratumumab and hyaluronidase-fihj and dexamethasone (ZDd), to treat adult multiple myeloma (MM) patients.